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It is well documented that disability accumulation in multiple sclerosis is correlated with axonal injury and that the extent of
axonal injury is correlated with the degree of inﬂammation. However, the interdependence between focal inﬂammation, diffuse
inﬂammation and neurodegeneration, and their relative contribution to clinical deﬁcits, remains ambiguous. A hypothesis might
be that early focal inﬂammation could be the pivotal event from which all else follows, suggesting the consideration of multiple
sclerosis as a two-stage disease. This prompted us to deﬁne two phases in the disease course of multiple sclerosis by using two
scores on the Kurtzke Disability Status Scale as benchmarks of disability accumulation: an early phase, ‘Phase 1’, from multiple
sclerosis clinical onset to irreversible Disability Status Scale 3 and a late phase, ‘Phase 2’, from irreversible Disability Status
Scale 3 to irreversible Disability Status Scale 6. Outcome was assessed through ﬁve parameters: Phase 1 duration, age at
Disability Status Scale 3, time to Disability Status Scale 6 from multiple sclerosis onset, Phase 2 duration and age at
Disability Status Scale 6. The ﬁrst three were calculated among all patients, while the last two were computed only among
patients who had reached Disability Status Scale 3. The possible inﬂuence of early clinical markers on these outcomes was
studied using Kaplan–Meier estimates and Cox models. The analysis was performed in the Rennes multiple sclerosis database
(2054 patients, accounting for 26273 patient-years) as a whole, and according to phenotype at onset (1609 relapsing/445
progressive onset). Our results indicated that the disability progression during Phase 2 was independent of that during Phase 1.
Indeed, the median Phase 2 duration was nearly identical (from 6 to 9 years) irrespective of Phase 1 duration (53, 3 to56, 6 to
510, 10 to515, 15 years) in the whole population, and in both phenotypes. In relapsing onset multiple sclerosis, gender, age
at onset, residual deﬁcit after the ﬁrst relapse and relapses during the ﬁrst 2 years of multiple sclerosis were found to be
independent predictive factors of disability progression, but only during Phase 1. Our ﬁndings demonstrate that multiple
sclerosis disability progression follows a two-stage process, with a ﬁrst stage probably dependant on focal inﬂammation and
a second stage probably independent of current focal inﬂammation. This concept has obvious implications for the future
therapeutic strategy in multiple sclerosis.
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Status Scale
doi:10.1093/brain/awq076 Brain 2010: 133; 1900–1913 | 1900
Received December 24, 2009. Revised February 22, 2010. Accepted March 8, 2010. Advance Access publication April 27, 2010
 The Author(s) 2010. Published by Oxford University Press on behalf of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5),
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Introduction
Several clinical courses are usually distinguished in multiple scler-
osis (Jekyll Island Meeting of MS Society 1995, reported in Lublin,
1996), but it remains uncertain whether they reﬂect different
neuropathological mechanisms. It is well established that axonal
injury is a feature of multiple sclerosis (Charcot, 1880), that the
extent of axonal injury is correlated with the degree of inﬂamma-
tion (Trapp et al., 1998) at least in relapsing multiple sclerosis, and
that a close association between inﬂammation and neurodegen-
eration might exist in all disease stages of multiple sclerosis
(Kutzelnigg et al., 2005; Frischer et al., 2009). However, the inter-
dependence between focal inﬂammation, diffuse inﬂammation
and neurodegeneration, and their relative contribution to clinical
deﬁcits remain ambiguous. Nevertheless, this point is central for
understanding the mechanism of tissue injury in multiple sclerosis,
which may have an effect on treatment.
It has been demonstrated that relapses produce a measurable
and sustained effect on disability progression in patients with
relapsing-remitting multiple sclerosis (Lublin et al., 2003), but
others did not ﬁnd a consistent effect of on-study relapses on
the subsequent development of sustained disability increase,
during a typical clinical study observation period (Young et al.,
2006). Moreover, a number of trials have suggested that
b-interferon has an impact on both relapses and disability progres-
sion at an early stage in patients with relapsing multiple sclerosis
and in patients with a ﬁrst clinical event suggestive of multiple
sclerosis, at least over a short-term period (Jacobs et al., 1996;
The PRISMS study group, 1998; Kappos et al., 2007). In contrast,
several observational studies about multiple sclerosis natural his-
tory (Confavreux et al., 2003, 2006a; Kremenchutzky et al., 2006)
showed that relapses did not inﬂuence disability progression in
patients who subsequently develop a secondary progressive
course, suggesting that focal inﬂammation may have only a
small inﬂuence on disability accumulation. Those studies also
showed that the median age at the onset of the progressive
phase was similar in secondary progressive cases and in primary
progressive cases, suggesting that multiple sclerosis may corres-
pond to a chronic neurodegenerative age-related disease that is
not affected by the initial course (Confavreux, 2006b). Moreover,
several well-designed trials in secondary progressive multiple scler-
osis (Rice et al., 2000; SPECTRIMS Study Group, 2001; Cohen
et al., 2002; Panitch et al., 2004) showed at this late stage an
apparent dissociation between the impact of therapeutics on
focal inﬂammatory markers (frequency of relapses and MRI
activity) and their impact on delaying disability progression in
the same time; suggesting that agents with a short term effect
on relapses may not necessarily delay the development of disabil-
ity in the long term.
A unifying hypothesis might be that early focal inﬂammation
could be the pivotal event from which all else follows
(Compston, 2006). Such a hypothesis implies that multiple scler-
osis is a two-stage disease, with a ﬁrst stage mainly dependent on
focal inﬂammation and a second stage dependent on diffuse in-
ﬂammation and neurodegeneration, but independent of current
focal inﬂammation. This prompted us to deﬁne two phases in
the multiple sclerosis disease course, an early phase and a late
phase. In this article we have reviewed the Rennes Multiple
Sclerosis database and attempted to contrast disability progression
in those two phases, as well as to identify potential predictive
factors of their duration.
Patients and methods
Patients and data collection
Patients were identiﬁed through the Rennes Multiple Sclerosis Clinic,
which is a regional referral centre for multiple sclerosis in West France
(Leray et al., 2007). Patients referred to Rennes Multiple Sclerosis
Clinic mainly live in Brittany (60%), Pays de Loire (20%) or bordering
regions (14%), the remainder coming from other French or European
regions (6%). Since January, 1976, any new case of multiple sclerosis
referred to our centre was systematically registered, whatever the date
of ﬁrst multiple sclerosis symptoms (from 1947 to 2004 in our series).
Historical data (date of clinical onset, symptoms at onset, relapses and
disability) were obtained at the ﬁrst visit, and follow-up data were
prospectively collected and entered into the medical records. In
1996, all these data were computerized using the standardized
European Database for Multiple Sclerosis (EDMUS) software
(Confavreux et al., 1992). From this time onwards, the Rennes
EDMUS database was regularly expanded with newly referred patients
and prospectively updated with data recorded at each follow-up visit.
Individual reports include the following information: identiﬁcation and
demographic data, medical history, multiple sclerosis course (ﬁrst
event, relapses, irreversible disability and progression) and treatments.
The database received approval from the French ‘Commission
Nationale Informatique et Liberte ´s’.
Deﬁnition of cases
By October, 2004, our database was locked with a total of 2290 cases.
For all of them, diagnosis of multiple sclerosis was established accord-
ing to Poser’s classiﬁcation (Poser et al., 1983). The date for the likely
ﬁrst symptom of the disease was considered to mark the clinical onset
of multiple sclerosis. A relapse of multiple sclerosis was deﬁned as the
occurrence, the recurrence or the worsening of symptoms of neuro-
logical dysfunction lasting over 24h and usually ending up in partial or
complete remission (Confavreux et al., 1992; Lublin, 1996), and a
progressive disease was deﬁned by at least 1 year of continuous de-
terioration, regardless of the rate of worsening that was not attribut-
able to relapses (Kremenchutzky et al., 2006). Disease phenotype at
onset was considered as either relapsing or progressive, and overall
multiple sclerosis course was categorized according to the standardized
classiﬁcation of multiple sclerosis (Lublin, 1996). However, we decided
to incorporate progressive-relapsing patients into the primary progres-
sive category, leading to three clinical multiple sclerosis courses:
relapsing-remitting, secondary progressive and primary progressive.
Clinical assessment
Disability was graded using the Kurtzke Expanded Disability Status
Scale (EDSS) (Kurtzke, 1983). However, for the data analysis, each
half unit was lumped with the corresponding whole unit, leading to
a reduction of the original 20-step EDSS to a 10-step scale, very similar
if not exactly similar to the original Disability Status Scale (DSS)
(Kurtzke, 1961). Residual deﬁcit from the ﬁrst relapse was deﬁned
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ible EDSS score of at least 2. For the data analysis on disability accu-
mulation, we have further reduced the scale by focusing on the
irreversible score 3 (deﬁned as moderate disability) and on the irre-
versible score 6 (deﬁned as unilateral assistance required to walk
100m). Those two scores can be quite easily identiﬁed in our data-
base, even when medical records are scored retrospectively. A score
was qualiﬁed as irreversible when it persisted for at least 6 months,
and up to the last visit.
Disability milestones
The two benchmarks of disability progression were the assignment of
an irreversible score of DSS 3 and DSS 6. Hypothesizing that DSS 3
corresponded to a key step in the disease process, we deﬁned two
phases in multiple sclerosis course: an early phase, ‘Phase 1’, from
clinical onset to irreversible DSS 3 and a later phase, ‘Phase 2’, from
irreversible DSS 3 to irreversible DSS 6. Outcome measurements con-
sisted in ﬁve parameters estimated in two different populations: time
to reach DSS 3 from multiple sclerosis clinical onset (‘Phase 1’ dur-
ation); age at DSS 3; time to reach DSS 6 from clinical onset of mul-
tiple sclerosis; time to reach DSS 6 from DSS 3 (’Phase 2’ duration);
and age at DSS 6. The ﬁrst three were estimated among all patients
with multiple sclerosis, while the last two were used only in those
patients who had reached DSS 3.
Moreover, to explore the relationship between disability progression
during ‘Phase 1’ and that during ‘Phase 2’, patients with multiple
sclerosis who had reached irreversible DSS 3 were classiﬁed into ﬁve
subgroups deﬁned according to ‘Phase 1’ duration (0 to53, 3 to56, 6
to 510, 10 to 515 and 15 years), the thresholds being selected to
give groups of comparable size, and to allow statistical comparisons.
Prognostic factors
Initial characteristics (gender, age, residual deﬁcit of the ﬁrst relapse
and number of relapses during the ﬁrst 2 years of multiple sclerosis)
were assessed as potential prognostic factors of ‘Phase 1’ and ‘Phase
2’ durations, in relapsing onset and progressive onset separately.
Duration of ‘Phase 1’ (considered as a categorical variable) and the
occurrence of relapses after DSS 3 were added as potential predictors
of ‘Phase 2’ duration.
Statistical analysis
Quantitative and qualitative variables were presented as number of
patients (%) and meanstandard deviation (SD), respectively, and
were compared using appropriate statistical tests.
Outcome measurements were analysed as survival data (event
deﬁned as either the attainment of DSS 3 or 6). Thus, whenever the
milestone had not been reached, data were censored at the date of
the last visit. The total number of patients, the number of patients
who reached the milestone (number of events) and the number of
censored patients are presented in the tables. Median times were
estimated using the Kaplan–Meier method (Kaplan, 1958), and sur-
vival curves were compared using the log-rank test. Inﬂuence of the
putative risk factors was then investigated using multivariate Cox
models (Cox, 1972).
P-values of less than 0.05 on two-tailed tests were considered as
statistically signiﬁcant. Statistical analysis was performed with Statistical
Package for the Social Sciences 15.0 for Windows (SPSS, 2002).
Results
Characteristics of the population
Of the 2290 patients registered in the database, 236 patients did
not meet the Poser criteria for clinically deﬁnite multiple sclerosis
and were excluded from the study. The demographic and clinical
characteristics according to initial multiple sclerosis course of the
2054 remaining patients are presented in Tables 1 and 2. Overall,
the sex ratio female:male was 2.30, the mean age at multiple
sclerosis clinical onset was 31.4  9.8 years, and the mean dur-
ation of follow-up from multiple sclerosis clinical onset to the last
visit was 12.89.4 years (accounting for 26273 patient-years).
During the follow-up period, 1415 patients (68.9%) reached irre-
versible DSS 3, of whom 718 patients (35%; 51.7% of those who
had reached DSS 3) reached irreversible DSS 6. Considering dis-
ease phenotype at onset, there were 445 patients (21.7%) with a
progressive onset disease and 1609 patients (78.3%) with a relap-
sing onset disease. In the latter group, 237 patients (14.9%) had
residual deﬁcit after the ﬁrst relapse, and 853 patients (53.0%)
had two relapses or more within the ﬁrst 2 years after clinical
onset (mean number of relapses during the ﬁrst 2 years of multiple
sclerosis: 1.81.2). During the follow-up, 618 patients with relap-
sing onset (38.4%) had converted to secondary progressive phase,
after a median time from multiple sclerosis clinical onset of 16.0
years (14.7–17.3) and at a median age of 40.4 years (39.3–41.4).
A total of 1154 patients (56.2%) received disease-modifying
drugs for at least 6 months, accounting for 4515 patient-years
spent with disease modifying drugs (17.2% of the total number
of patient-years; 16.9% in the relapsing onset and 18.1% in the
progressive onset, non-signiﬁcant difference). Treatment was
started 7.77.1 years after clinical onset of multiple sclerosis on
average, and consisted of b-interferon (28.5%), mitoxantrone
(26.7%), azathioprine (21.4%), methotrexate (13.0%), cyclophos-
phamide (6.7%) and glatiramer acetate (2.2%).
Among the 2054 patients, 540 patients (26.3%) had their last
follow-up visit within the year preceding the closing of the data-
base, 1042 patients (50.7%) within the previous 2 years and 1337
patients (65.1%) within the previous 3 years. Only 14.2% of pa-
tients did not have updated information in the 5 years preceding
the closing of the database for analysis. Disease characteristics and
disability progression did not differ according to the delay between
the closing of the database and the last visit at the Multiple
Sclerosis Centre (within the last 2 years versus before the last
2 years, data not shown).
Disability progression during Phase 1
and Phase 2
To evaluate the potential relationship between disability progres-
sion during Phase 1 and Phase 2, we focused on the 1415 patients
with multiple sclerosis (995 patients with relapsing onset and 420
patients with progressive onset) who reached DSS 3, and classiﬁed
them into ﬁve subgroups according to Phase 1 duration: subgroup
1( 0t o53 years, 523 patients), subgroup 2 (3 to 56 years, 290
patients), subgroup 3 (6 to 510 years, 254 patients), subgroup 4
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patients). For progressive onset multiple sclerosis, due to the low
number of patients, the subgroups over 6 years were collapsed
into one, leading to three subgroups (0 to53 years, 270 patients;
3t o56 years, 90 patients; 6 years, 60 patients). Two categories
of patients were described in the analysis: those who had reached
DSS 6, and those who had not. Among the 718 patients who had
reached DSS 6, the mean time to reach DSS 6 from DSS 3 was
5.47 years, with variations from 3.8 to 6.4 years when considering
each year of duration of Phase 1 (data not shown). Almost iden-
tical mean times were observed in the ﬁve subgroups of Phase 1
duration, either in the whole multiple sclerosis population
(between 4.88 and 5.74 years, P=0.764), in relapsing onset
multiple sclerosis (between 4.93 and 6.31 years, P=0.394), or in
progressive onset multiple sclerosis (between 4.74 and 6.10 years,
P=0.444) (Table 3).
Table 1 Demographic characteristics of patients in the whole multiple sclerosis population and according to the disease
phenotype at onset of multiple sclerosis
All multiple
sclerosis patients
Disease phenotype at onset of multiple sclerosis P-value
a
Relapsing onset Progressive onset
Number of patients 2054 1609 445 –
Female:male sex ratio 2.30 (1431:623) 2.67 (1171:438) 1.41 (260:185) 50.001
Mean age at onset of multiple sclerosis (years)SD 31.49.8 29.58.8 38.510.1 50.001
Age group at onset of multiple sclerosis 0.0001
520 years 236 (11.5%) 223 (13.9%) 13 (2.9%)
20 to 530 years 771 (37.5%) 688 (42.8%) 83 (18.7%)
30 to 540 years 630 (30.7%) 488 (30.3%) 142 (31.9%)
40 to 550 years 337 (16.4%) 183 (11.4%) 154 (34.6%)
50 years 80 (3.9%) 27 (1.7%) 53 (11.9%)
Initial symptoms of multiple sclerosis (n=1876) 50.001
Isolated long tracts 962 (51.3%) 686 (45.3%) 276 (76.0%)
Isolated brainstem 218 (11.6%) 216 (14.3%) 2 (0.6%)
Isolated optic neuritis 404 (21.5%) 367 (26.2%) 7 (1.9%)
Combined symptoms 292 (15.6%) 214 (14.1%) 78 (21.5%)
Mean follow-up duration from onset (years)SD 12.89.4 13.19.8 11.47.9 50.001
a Comparison relapsing onset versus progressive onset.
Table 2 Disability characteristics of patients in the whole multiple sclerosis population and according to the disease
phenotype at onset of multiple sclerosis
All multiple
sclerosis patients
Disease phenotype at onset of
multiple sclerosis
P-value
a
Relapsing onset Progressive onset
All patients 2054 1609 445 –
Patients with a progressive course – 618 (38.4%) 445 (100.0%) –
Patients who had reached DSS 3 during follow-up 1415 (68.9%) 995 (61.8%) 420 (94.4%) 50.001
Patients who had reached DSS 6 during follow-up 718 (35.0%) 467 (29.0%) 251 (56.4%) 50.001
Median time to progression onset from multiple sclerosis
clinical onset (years)
b
– 16.0 (14.7 – 17.3) 0 –
Median time to DSS 3 from multiple sclerosis
clinical onset (years)
b
7.4 (6.9–7.9) 10.0 (9.4–10.6) 2.0 (1.8–2.2) 50.0001
Median time to DSS 6 from multiple sclerosis
clinical onset (years)
b
18.0 (16.8–19.2) 21.7 (20.6–22.9) 10.0 (9.1–10.9) 50.0001
Median age at the assignment of DSS 3 (years)
b 42.3 (41.742.8) 42.4 (41.6–43.1) 41.9 (40.8–42.9) 0.236
Patients who had reached DSS 3 1415 995 420 –
Median time to DSS 6 from EDSS 3 (years)
b 7.0 (6.4–7.6) 7.4 (6.8–8.0) 6.6 (6.2–7.0) 0.003
Median age at the assignment of DSS 6 (years)
b 51.4 (50.1–52.6) 51.1 (49.7–52.6) 52.1 (49.7–54.6) 0.915
a Comparison relapsing onset versus progressive onset.
b Kaplan–Meier estimated median with 95% conﬁdence interval; comparison of survival curves using LogRank test.
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DSS 6 did not differ signiﬁcantly in the ﬁve different subgroups
of the whole multiple sclerosis population (45.5–54.7%), of
relapsing onset multiple sclerosis (43.9–56.5%) and of progres-
sive onset multiple sclerosis (55.0–61.5%). To exclude any bias
potentially linked to a shorter follow-up duration of patients
who had not reached DSS 6, we also compared the mean
time to reach DSS 6 from DSS 3 in patients who had reached
EDSS 6 with the mean time of follow-up from DSS 3 to the
last visit in patients who had not reach DSS 6. No signiﬁcant
difference was found when considering overall data (718 versus
697 patients, respectively), and each subgroup of Phase 1
duration.
Moreover, the Kaplan–Meier method allowed us to calculate the
median time to reach DSS 6 from DSS 3 by taking into account
censored data (the time from DSS 3 to the last visit for patients
who had not reached DSS 6). This conﬁrmed that the duration of
Phase 2 was nearly identical irrespective of the duration of Phase 1
in the whole multiple sclerosis population (from 6.8 to 9.2 years,
P=0.651), in relapsing onset multiple sclerosis (from 6.5 to 9.2
years, P=0.073) and in progressive onset multiple sclerosis (from
6.0 to 7.0 years, P=0.118).
As a large part of our population received disease-modifying
treatments, and the impact of those treatments is not well
known on the long-term disability progression, we performed
the same analysis on the untreated population (n=900). In this
population, we conﬁrmed that almost identical mean durations of
Phase 2 were observed in the ﬁve subgroups of Phase 1 duration,
either in the whole multiple sclerosis population, in relapsing onset
multiple sclerosis or in progressive onset multiple sclerosis (data
not shown).
Finally, of the 995 patients with relapsing onset who had
reached DSS 3, 416 patients (41.8%) had converted into
secondary progressive multiple sclerosis during Phase 1,
which indicated that conversion into secondary progressive
multiple sclerosis was not concomitant with the assignment
of DSS 3.
In summary, these results indicated that the disability progres-
sion during Phase 2 is independent of the disability progression
during Phase 1, as clearly illustrated in Fig. 1.
Age and disease duration to disability
milestones DSS 3 and DSS 6 according
to disease phenotype at multiple
sclerosis onset (relapsing or
progressive onset)
To assess the relationship between disease progression and the
phenotype at multiple sclerosis clinical onset, we separately
examined relapsing onset and progressive onset multiple sclerosis
with respect to the time to reach the two disability milestones
(DSS 3 and DSS 6) from multiple sclerosis clinical onset
(i.e. disease duration) or from birth (i.e. age). The proportion
of patients who had reached both irreversible DSS 3 and 6
were signiﬁcantly higher in progressive onset multiple sclerosis
than in relapsing onset multiple sclerosis (DSS 3: 94.4 versus
61.0%, respectively, P50.001; DSS 6: 56.4 versus 29.0%,
P50.001). This would indicate that multiple sclerosis with
progressive onset had a more rapid disability progression than
multiple sclerosis with relapsing onset during a given follow-up
period, as will be demonstrated below. As expected, patients
with progressive onset multiple sclerosis were older at onset
than those with relapsing onset (median 39.0 versus 28.4
years, P50.0001; Fig. 2). However, their age at the assignment
of both DSS 3 and 6 did not differ signiﬁcantly from that of
multiple sclerosis patients with relapsing onset (median age at
DSS 3: 41.9 versus 42.4 years, respectively; P=0.236; median
age at DSS 6: 52.1 versus 51.1 years, respectively, P=0.915).
On the contrary, the median durations from multiple sclerosis
clinical onset to both DSS 3 and 6 were signiﬁcantly shorter in
progressive onset multiple sclerosis than in relapsing onset mul-
tiple sclerosis (DSS 3: 2.0 versus 10.0 years, respectively,
P50.0001; DSS 6: 10.0 versus 21.7 years respectively, P 5
0.0001). The median duration of Phase 2 (time to reach DSS
6 from DSS 3) was also shorter in progressive compared to
patients with relapsing onset multiple sclerosis but the difference
was less signiﬁcant (6.6 versus 7.4 years, respectively, P50.003)
(Table 4).
In summary, the disease phenotype at multiple sclerosis onset
was found to be correlated not only with age at onset, but also
Figure 1 Disability progression during Phase 2 (mean time from DSS 3 to DSS 6) in ﬁve subgroups deﬁned according to the duration of
Phase 1 (mean time from multiple sclerosis clinical onset to DSS 3) in the 718 multiple sclerosis patients who had reached both DSS 3 and
DSS 6.
Two-stage disability progression in MS Brain 2010: 133; 1900–1913 | 1905with the disability progression. While patients with relapsing and
progressive multiple sclerosis onset reached DSS 3 and DSS 6 at
the same age, our data showed that the progressive onset pheno-
type signiﬁcantly shortened the duration of Phase 1, and to a
lesser extent the duration of Phase 2, compared with the relapsing
onset phenotype.
Age and disease duration to disability
milestones DSS 3 and DSS 6 according
to gender
Although males and females had the same age at multiple sclerosis
clinical onset (median 30.2 years, P =0.784), males were signiﬁ-
cantly younger than females when they reached the two disability
milestones (DSS 3: 40.4 versus 42.7 years, P50.0001; DSS 6: 49.7
versus 52.2 years, P 50.010; Fig. 2). Consistently, the time to
reach DSS 3 from clinical onset of multiple sclerosis was shorter
in males than in females (median 6.0 versus 8.0 years,
P50.0001). The time to reach DSS 6 from clinical onset of mul-
tiple sclerosis was also shorter in males than in females (median
16.0 versus 20.0 years, respectively, P50.0001), but not the time
to reach DSS 6 from DSS 3 (median 7.0 years in both genders,
P=0.404; Table 4). In the same line, although the follow-up dur-
ation from multiple sclerosis clinical onset was similar in males and
females (13.38.8 years and 12.69.7 years, respectively,
P=0.119), males had more frequently reached both disability
milestones than females (DSS 3: 76.6 versus 66.5%, respectively,
P50.0001; DSS 6: 42.5 versus 31.7%, respectively, P50.0001).
This might be due to the fact that the ‘progressive onset:relapsing
onset’ ratio was higher in males. We thus examined gender effect
according to the disease phenotype at onset. In the group of
patients with progressive onset multiple sclerosis, males had a
younger age than women, the difference being signiﬁcant both
at multiple sclerosis onset (median 37.6 versus 39.9 years,
P50.004) and at DSS 3 (median 40.4 versus 42.5 years,
P50.004), and almost signiﬁcant at DSS 6 (median 51.0 versus
53.8 years, P=0.09). In addition, males and females with progres-
sive onset had similar durations of both Phase 1 (median
2.0 years, P=0.871) and Phase 2 (6.8 versus 6.0 years,
P=0.832). On the contrary, in the group of patients with relap-
sing onset multiple sclerosis, males and females had similar age at
onset (median 28.4 versus 28.5 years, respectively, P=0.881), but
men reached DSS 3 at a younger age than women (median 40.6
versus 42.8 years, P50.005), and DSS 6 as well (median 49.3
versus 51.8 years, P50.048). Consistently, in relapsing onset mul-
tiple sclerosis, the duration of Phase 1 was shorter in males than in
females (9.0 versus 10.0 years, P50.005), while the duration of
Phase 2 was similar in both genders (7.0 versus 7.7 years,
P=0.371).
Figure 2 Kaplan–Meier estimated median age at multiple sclerosis clinical onset and at DSS score of 3 in the 2054 patients with multiple
sclerosis, and Kaplan-Meier estimated median age at DSS score of 6 in the 1415 patients who had reached DSS 3, according to (i) disease
phenotype at onset, (ii) gender and (iii) gender by disease phenotype at onset. Asterisk denotes the signiﬁcant comparison (P50.05,
progressive versus relapsing onset, and females versus males, respectively).
1906 | Brain 2010: 133; 1900–1913 E. Leray et al.Interestingly, males with progressive or relapsing onset mul-
tiple sclerosis reached DSS 3 at the same age (median 40.4
versus 40.6 years, P=0.363) as did females (median 42.5
versus 42.8 years, P=0.710), supporting the idea that gender
rather than phenotype at onset inﬂuenced the age at the assign-
ment of DSS 3.
In summary, when males were compared with females, they
were characterized by a younger age at clinical onset in progres-
sive onset multiple sclerosis only, a shorter Phase 1 duration in
relapsing onset multiple sclerosis only and a younger age at
DSS 3 in both phenotypes. On the contrary, gender did not inﬂu-
ence the duration of Phase 2, whatever the disease phenotype
at onset.
Age and disease duration to disability
milestones DSS 3 and DSS 6 according
to age at clinical onset of multiple
sclerosis
Considering age at onset as a categorical variable, we looked for a
correlation between age at onset and disability progression. First,
the younger the age at onset, the younger were the median ages
at both EDSS 3 and 6. The age at DSS 3 signiﬁcantly increased
from the youngest to the oldest age group at onset (median from
29.8 to 57.1 years, P50.0001). The same was true for the age at
DSS 6 (median from 41.5 to 65.0 years, P50.0001). Those cor-
relations were observed in both relapsing onset and progressive
onset multiple sclerosis (Fig. 3). Second, the younger the age at
onset, the longer were the durations from clinical onset of mul-
tiple sclerosis to irreversible DSS 3 and 6. Indeed, the median
times from multiple sclerosis clinical onset to DSS 3 signiﬁcantly
decreased as age of multiple sclerosis onset increased. Only the
group of relapsing onset multiple sclerosis accounted for this
correlation (median from 14.4 years to 3.3 years, P50.0001),
which was not observed in the group of patients with progressive
onset multiple sclerosis (median 2.0 years for all age groups,
P=0.295). The median times from clinical onset of multiple
sclerosis to DSS 6 also decreased with increasing age at onset
(median from 29.0 to 9.0 years, P50.0001). On the contrary,
the time from DSS 3 to DSS 6 remained stable irrespective of
the age group at onset (between 6.0 and 7.5 years, P=0.122;
Table 4).
Table 4 Potential risk factors affecting the median times from clinical onset of multiple sclerosis to the assignment of
irreversible DSS score of 3 (Phase 1), and to the assignment of irreversible DSS score of 6 among the 2054 patients with
multiple sclerosis, and the median time from DSS 3 to the assignment of an irreversible DSS score of 6 (Phase 2) among the
1415 patients with multiple sclerosis who had reached DSS 3
Variables Time from multiple sclerosis clinical
onset to DSS 3 (years) (n=2054)
Time from multiple sclerosis clinical
onset to DSS 6 (years) (n=2054)
Time from DSS 3 to
DSS 6 (years) (n=1415)
Number
of
events
Number
of
censored
Kaplan–Meier
estimated
median
a
Number
of
events
Number
of
censored
Kaplan–Meier
estimated
median
a
Number
of
events
Number
of
censored
Kaplan–Meier
estimated
median
a
All 1415 639 (31.1%) 7.4 (6.9–7.9) 718 1336 (65.0%) 18.0 (16.8–19.2) 718 697 (49.3%) 7.0 (6.4–7.6)
Phenotype
Relapsing onset 995 614 (38.2%) 10.0 (9.4–10.6) 467 1142 (71.0%) 21.7 (20.6–22.9) 467 528 (53.1%) 7.4 (6.8–8.0)
Progressive onset 420 25 (5.6%) 2.0 (1.8–2.2) 251 194 (43.6%) 10.0 (9.1–10.9) 251 169 (40.2%) 6.6 (6.2–7.0)
P50.0001 P50.0001 P50.003
Gender
Male 477 146 (12.4%) 6.0 (5.3–6.7) 265 358 (57.5%) 16.0 (15.0–17.0) 265 212 (44.4%) 7.0 (6.3–7.7)
Female 938 493 (34.5%) 8.0 (7.5–8.5) 453 978 (68.3%) 20.0 (18.4–21.6) 453 485 (51.7%) 7.0 (6.4–7.6)
P50.0001 P50.0001 P=0.404
Gender by phenotype
Relapsing onset
Male 302 136 (31.1%) 9.0 (7.6–10.4) 158 280 (63.9%) 18.0 (15.8–20.2) 158 144 (47.7%) 7.0 (5.7–8.3)
Female 693 478 (40.8%) 10.0 (9.1–10.9) 309 862 (73.6%) 22.7 (21.3–24.1) 309 384 (55.4%) 7.7 (7.0–8.5)
Progressive onset P50.005 P50.006 P=0.371
Male 175 10 (5.4%) 2.0 (1.6–2.4) 107 78 (42.2%) 10.1 (9.1–11.1) 107 68 (38.9%) 6.8 (6.3–7.3)
Female 245 15 (5.8%) 2.0 (1.8–2.2) 144 116 (44.6%) 9.5 (8.4–10.6) 144 101 (41.2%) 6.0 (5.0–7.0)
P=0.871 P=0.847 P=0.832
Age at multiple
sclerosis onset (years) 142 94 (39.8%) 14.0 (12.1–15.9) 76 160 (67.8%) 29.0 (23.1–34.9) 76 66 (46.5%) 7.3 (6.1–8.5)
520 496 275 (35.7%) 10.2 (9.2–11.2) 258 513 (66.5%) 21.0 (19.6–22.4) 258 238 (48.0%) 7.5 (7.0–8.0)
20 to 530 445 185 (29.4%) 6.3 (5.7–7.0) 230 400 (63.5%) 16.8 (15.4–18.3) 230 215 (48.3%) 6.7 (6.2–7.2)
30 to 540 263 74 (22.0%) 3.5 (3.0–4.0) 117 220 (65.3%) 12.7 (11.1–14.3) 117 146 (55.5%) 6.5 (5.8–7.3)
40 to 550 69 11 (13.8%) 2.2 (1.8–2.7) 37 43 (53.8%) 9.0 (7.6–10.4) 37 32 (46.4%) 6.0 (4.6–7.4)
50 P50.0001 P50.0001 P=0.122
a Kaplan–Meier estimated median time with 95% conﬁdence interval; comparison of survival curves using LogRank test.
Two-stage disability progression in MS Brain 2010: 133; 1900–1913 | 1907In summary, a strong correlation was found between age at
onset and disability progression in the whole multiple sclerosis
population, and especially in relapsing onset multiple sclerosis.
While patients younger at onset were also younger when reaching
DSS 3 and 6, they exhibited a slower disability progression during
Phase 1. On the contrary, age at onset did not inﬂuence the
duration of Phase 2.
Age and disease duration to disability
milestones DSS 3 and DSS 6 according
to relapse history in relapsing onset
multiple sclerosis
Results on relapse history are presented in Table 5. First, the pres-
ence of residual deﬁcit (EDSS2) after the ﬁrst relapse was
strongly correlated with subsequent disability progression.
Patients with early residual deﬁcit reached DSS 3 more rapidly
than others (median 5.0 versus 11.0 years, respectively,
P50.0001). They also reached DSS 6 more rapidly (median 18.0
versus 22.0 years, respectively, P50.0001), despite a slightly
longer Phase 2 than patients without residual deﬁcit after the
ﬁrst relapse (median 8.2 versus 7.0 years, respectively, P50.011).
Second, the number of relapses during the ﬁrst 2 years in pa-
tients with relapsing multiple sclerosis onset was strongly corre-
lated with a shorter duration from multiple sclerosis clinical onset
to DSS 3 (median 7.7 years if two relapses or more versus 12.2
years if only one relapse, P50.0001), and to DSS 6 (median 20.3
versus 22.3 years, P50.001), but did not modify the duration
from DSS 3 to DSS 6 (7.7 versus 7.0 years, respectively,
P=0.200).
Third, we focused on patients with relapsing onset multiple
sclerosis who had reached DSS 3 and assessed, in this subgroup,
the inﬂuence of relapses occurring after DSS 3. At ﬁrst, the occur-
rence of relapses after DSS 3 would appear negatively correlated
with the time to reach DSS 6 from DSS 3, since patients without
Figure 3 Kaplan–Meier estimated median age at clinical onset of multiple sclerosis and at DSS score of 3 in the 2054 patients with
multiple sclerosis, and age at DSS score of 6 in the 1415 patients, who had reached DSS 3, according to age at onset, in the total multiple
sclerosis population and in patients with multiple sclerosis classiﬁed by disease phenotype at multiple sclerosis onset.
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Two-stage disability progression in MS Brain 2010: 133; 1900–1913 | 1909relapses after DSS 3 had a shorter Phase 2 than patients who
experienced relapses (median 6.0 versus 8.9 years, respectively,
P50.0001). However, up to 64.3% of them had converted into
secondary progressive multiple sclerosis during Phase 1, and only
20.3% of those who had relapses during Phase 2 (P50.0001).
Thus, to evaluate the real impact on disability progression of
relapses occurring during Phase 2, we excluded the 416 patients
who had converted to secondary progressive multiple sclerosis at
DSS 3 or before. Among the 579 patients whose disease was still
relapsing at DSS 3, Phase 2 was longer among patients without
relapses after DSS 3 than among patients who experienced re-
lapses, but the difference was not signiﬁcant (median 12.0
versus 9.0 years, P=0.677), which allowed us to collapse these
two groups into one. Finally, the 579 patients still relapsing at DSS
3 (with or without relapses) were found to have a longer Phase 2
than the 416 patients with secondary progressive multiple sclerosis
(median 9.1 versus 6.0 years, P50.0001).
In summary, in relapsing onset multiple sclerosis, the presence
of a residual deﬁcit after the ﬁrst relapse and the occurrence of
relapses during the ﬁrst two years of multiple sclerosis signiﬁcantly
shortened the duration of Phase 1 but did not inﬂuence disability
progression during Phase 2. During Phase 2, disability progression
was more inﬂuenced by a previous conversion to secondary pro-
gressive than by occurrence of relapses.
Independent predictive factors of
disability progression in Phases 1 and 2
using multivariate analysis according to
disease phenotype at onset
In relapsing onset multiple sclerosis, factors detected by Kaplan–
Meier analyses as inﬂuencing disability progression during Phase 1
(i.e. gender, age at multiple sclerosis onset, residual deﬁcit after
the ﬁrst relapse and relapses during the ﬁrst 2 years of multiple
sclerosis) were used as covariates in the Cox multivariate model.
All were identiﬁed as independent predictive factors of disability
progression during Phase 1. Likewise, the multivariate Cox model
conﬁrmed that only two factors (residual deﬁcit after the ﬁrst re-
lapse, and early conversion into secondary progression) were pre-
dictive of the duration of Phase 2. In particular, the duration of
Phase 2 was not inﬂuenced by the duration of Phase 1 (deﬁned as
a categorical variable).
Table 6 Results from Cox models about potential risk factors affecting the time from multiple sclerosis clinical onset to the
assignment of an irreversible DSS score of 3 (Phase 1) among the 1609 patients with relapsing onset multiple sclerosis, and
the time from DSS 3 to the assignment of an irreversible DSS score of 6 (Phase 2) among the 995 patients with relapsing
onset multiple sclerosis who had reached DSS 3
Variable Time from multiple sclerosis
clinical onset to DSS 3 (n=1609)
Time from DSS 3 to DSS 6 (n=995)
Hazard ratio
(95% conﬁdence interval)
P-value Hazard ratio
(95% conﬁdence interval)
P-value
Gender 0.004 0.729
Male 1 1
Female 1.22 (1.06–1.40) 1.04 (0.85–1.27)
Age at multiple sclerosis clinical onset (years) 0.0001 0.223
520 1 1
20 to 530 1.32 (1.08–1.60) 1.02 (0.77–1.35)
30 to 540 1.64 (1.34–2.02) 1.06 (0.78–1.44)
40 to 550 2.94 (2.28–3.79) 1.13 (0.76–1.70)
50 4.28 |2.56–7.14) 1.61 |0.75–3.44)
Number of relapses during the ﬁrst 2 years
of multiple sclerosis
0.0001 0.536
11 1
2 1.77 (1.56–2.02) 0.94 (0.77–1.15)
Residual deﬁcit from the ﬁrst relapse 0.0001 0.021
No 1 1
Yes 2.44 (2.07–2.88) 0.72 (0.55–0.95)
Time from multiple sclerosis clinical onset
to DSS 3 (years)
– – 0.240
0t o53 – 1.10 (0.78–1.55)
3t o56 – 0.95 (0.69–1.31)
6t o510 – 1.16 (0.85–1.59)
10 to 515 – 1.32 (0.97–1.79)
15 1
Conversion to secondary progression at
DSS 3 or before
– – 0.0001
No – 1
Yes 1.62 (1.33–1.98)
1910 | Brain 2010: 133; 1900–1913 E. Leray et al.As for progressive onset multiple sclerosis, no factor was found
to be associated with disability progression during Phase 1 (neither
gender, nor age at multiple sclerosis clinical onset) and Phase 2
(neither gender, nor age at multiple sclerosis clinical onset, nor
duration of Phase 1; data not shown) (Table 6).
Discussion
In our population of 2054 patients referred to the Rennes Multiple
Sclerosis Clinic in France, the age and sex distributions were similar
to those previously reported (Weinshenker et al., 1989b; Phadke,
1990; Runmarker, 1993; Confavreux et al., 2000; Tremlett et al.,
2006). In most series, including ours, the follow-up duration from
onset of multiple sclerosis was 10–12 years (Phadke, 1990;
Runmarker, 1993; Confavreux et al., 2000, 2003), except for
the Canadian cohorts where it was 20 years (Tremlett et al.,
2006) and 25 years (Kremenchutzky et al., 2006). In our series,
there were 445 patients (21.7%) with a progressive onset disease.
The proportion of primary progressive patients in the published
series varies from 12.4% (352/2837) in Vancouver (Tremlett
et al., 2006), 15.3% (282/1844) in Lyon (Confavreux et al.,
2000), 19.8% (216/1089) in London Ontario (Cottrell et al.,
1999), to 33.7% (367/1089) in the initial paper coming from
London Ontario (Weinshenker et al., 1989a). There is at present
no good explanation for these differences (except for the last one,
as some misclassiﬁcations were identiﬁed in a second assessment).
Unlike the other multiple sclerosis populations, a large proportion
of our patients received disease-modifying treatments, and time
spent on disease modifying drugs was 17.2% of the total
follow-up. Nevertheless, to date, there is no proven efﬁcacy of
those treatments on reducing the long-term progression of irre-
versible disability in multiple sclerosis. Moreover, our database was
closed in 2004, i.e. before the new therapeutic strategies in favour
of a treatment administered earlier in multiple sclerosis history.
Indeed, none of our patients received a treatment after the ﬁrst
episode (mean multiple sclerosis duration before the ﬁrst treat-
ment: 7.7 years), and when restricting the analysis to the untreat-
ed population our results on the two phases remained similar. The
time from multiple sclerosis clinical onset to reach DSS 6 in our
population was in line with those found in the main multiple scler-
osis series (about 18–20 years in relapsing onset in both Lyon
cohort (Confavreux et al., 2000) and London Ontario cohort
(Weinshenker et al., 1989a; Kremenchutzky et al., 2006) what-
ever the mean follow-up duration (11 years in Lyon cohort, 25
years in London Ontario cohort), but was lower than in British
Columbia (27.9 years; Tremlett et al., 2006). A methodological
reason may account for this difference as pinpointed by
Confavreux (2008): Tremlett et al. are the only authors who
excluded the patients who had already reached the selected out-
come before the ﬁrst visit at the Multiple Sclerosis Clinic
(left-censored patients), resulting in a potential over-estimation
of the times to disability milestones.
In this observational study we clearly demonstrate that disability
progression in the ﬁrst phase of multiple sclerosis (deﬁned by the
period until irreversible DSS 3) does not inﬂuence disability pro-
gression during the second phase (deﬁned by the period from
irreversible DSS 3 to irreversible DSS 6). Contrasting with the
high variability of Phase 1 duration, the Phase 2 duration remained
remarkably constant, as previously shown in the British Columbia
multiple sclerosis population (Tremlett et al., 2006). In this article,
the median time from EDSS 3 to EDSS 6 was estimated between
4.4 and 6.8 years in the four subgroups deﬁned according to the
time to EDSS 3 from onset (55, 5 to510, 10 to515, 15 years).
While some authors (Confavreux et al., 2000, 2003; Confavreux,
2006a, b; Debouverie et al., 2008) used a score of 4 as early
benchmark of disability accumulation, we chose to use the score
of 3. Indeed, during the data collection we paid a special attention
to this hallmark, as did others (Weinshenker et al., 1989; Cottrell
et al., 1999; Kremenchutzky et al., 2006; Tremlett et al., 2006). In
our opinion, more than the choice of score on the disability scale,
the important fact is that both deﬁne an early and reliable thresh-
old of irreversible disability.
We also conﬁrmed previous results showing the role of pheno-
type on disability progression. In relapsing onset multiple sclerosis,
the disability progression during Phase 1 was much slower, and
that during Phase 2 was somehow slower, than in progressive
onset multiple sclerosis. Phenotype also inﬂuenced the age at
onset, but not the age at DSS 3 and DSS 6. This was in line
with some reports (Confavreux, 2006a; Kremenchutzky et al.,
2006; Koch et al., 2007) showing that the age at the onset of
progression was not signiﬁcantly different between secondary pro-
gressive and primary progressive multiple sclerosis.
Our most important and original result was the ﬁnding that the
factors inﬂuencing disability progression during Phase 1 were re-
stricted to relapsing onset multiple sclerosis. These comprised
gender, age at multiple sclerosis onset and relapse history (relapses
within the ﬁrst 2 years, and residual deﬁcit after the ﬁrst relapse).
In relapsing onset multiple sclerosis, gender inﬂuenced disability
progression during Phase 1 only. Females had a slower progres-
sion, and thus were older at DSS 3 and DSS 6 than males. In
progressive onset multiple sclerosis, although males were younger
at onset of DSS 3 and DSS 6 than females, gender did not inﬂu-
ence the disability progression during Phase 1 and Phase 2. Other
studies on the whole multiple sclerosis population have showed a
slower disability progression in females than in males
(Weinshenker et al., 1989b; Runmarker, 1993; Confavreux
et al., 2003). One of these studies (Confavreux et al., 2003)
also showed that in the whole multiple sclerosis population,
gender inﬂuenced the time from multiple sclerosis clinical onset
to DSS 4, but not the time from DSS 4 to DSS 6 or 7. Our data
demonstrated that only the relapsing onset phenotype accounted
for this observation.
In relapsing onset multiple sclerosis, age at multiple sclerosis
clinical onset deserves special consideration as it dramatically inﬂu-
enced the disability progression during Phase 1 (but not during
Phase 2); the younger the age at onset, the slower the disability
progression during Phase 1. In contrast, in progressive onset mul-
tiple sclerosis, age at onset did not inﬂuence disability progression
during Phase 1 and Phase 2. Age at onset also inﬂuenced age at
DSS 3 and DSS 6 in both phenotypes: the younger the age at
onset, the younger the age at DSS 3 and DSS 6. While the inﬂu-
ence of age at onset has already been described in the whole
multiple sclerosis population (Phadke, 1990; Runmarker, 1993;
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our data demonstrated that only the relapsing onset phenotype
accounted for this observation.
In relapsing onset multiple sclerosis, the occurrence of at least
two relapses during the ﬁrst 2 years of multiple sclerosis and the
presence of residual deﬁcit from the ﬁrst relapse made the disabil-
ity progression faster during Phase 1. The correlation between
early relapses and early disability progression has also been
shown in previous studies (Weinshenker et al., 1989b;
Confavreux et al., 2000; Lublin et al., 2003; Tremlett et al.,
2009). In contrast, relapses after DSS 3 did not have a similar
inﬂuence on disability progression in the large majority of patients
with multiple sclerosis. However, when secondary progressive mul-
tiple sclerosis was excluded, the relapses after DSS 3 might still
have some inﬂuence on disability, although the comparison did
not reach statistical signiﬁcance due to the small numbers of pa-
tients. More than the occurrence of relapses, the conversion to
secondary progressive multiple sclerosis inﬂuenced disability pro-
gression in Phase 2. The dissociation between later relapses and
later disability progression has already been observed (Confavreux
et al., 2000, 2003; Kremenchutzky et al., 2006; Young et al.,
2006; Tremlett et al., 2009). Our data pointed out the inﬂuence
of early focal inﬂammatory clinical markers on disability progres-
sion restricted to Phase 1.
Finally, the Cox multivariate analysis conﬁrmed that all the
above factors were independently predictive of disability progres-
sion during Phase 1 in relapsing onset multiple sclerosis. While
these factors have already been identiﬁed in the whole multiple
sclerosis population (Weinshenker et al., 1989b; Phadke, 1990;
Runmarker, 1993, Kantarci et al., 1998; Confavreux et al.,
2003; Ebers, 2005), we demonstrated that their inﬂuence was
restricted to the duration of Phase 1 and to the relapsing onset
phenotype. Indeed, except for the conversion to secondary pro-
gressive multiple sclerosis and the presence of a residual deﬁcit
after the ﬁrst relapse, we did not ﬁnd a clear predictive factor of
disability progression after irreversible DSS 3 in relapsing onset
multiple sclerosis, or during Phases 1 and 2 in progressive onset
multiple sclerosis. This was consistent with other observational
studies (Confavreux et al., 2003; Debouverie et al., 2008) yielding
the conclusion that once a clinical threshold of irreversible disabil-
ity is reached, the progression of disability is amnesic of the prior
clinical history of the disease.
The understanding about the dissociation between early and
later disability progression and about the role of prognostic factors
is central to the debate on the putative mechanisms of disability
progression in multiple sclerosis. Some studies (Confavreux,
2006b; Kremenchutzky et al., 2006, Stankoff et al., 2007) have
suggested that age is a key player (if not the only one) in the
natural history of multiple sclerosis, leading to the concept of mul-
tiple sclerosis as a single-stage disorder with a chronic age-related
neurodegeneration since the onset of the disease (Confavreux,
2006a). However, our data gave evidence for a two-stage disabil-
ity progression in multiple sclerosis. In relapsing onset phenotype,
the independency between Phase 1 and Phase 2 suggested a
two-stage disease, with a ﬁrst stage during which focal inﬂamma-
tory lesions inﬂuence disability progression and a second stage
during which disability progression is independent of focal
inﬂammatory markers. In contrast, in progressive onset pheno-
type, focal inﬂammatory lesions are clinically asymptomatic for
a long period of time and only detectable on MRI, restricting
the clear identiﬁcation of the ﬁrst stage of the disease. This con-
cept of multiple sclerosis as a two-stage disease is not contradict-
ory with the inﬂuence of age in disability progression. Age might
inﬂuence the multiple sclerosis course in different ways:
age-related decrease in central nervous system remyelination
(Stankoff et al., 2007), age-related plasticity of brain injury
(Compston, 2008) and age-related change in immune factors
(Weiner, 2009).
The concept of multiple sclerosis as a two-stage disease is also
supported by some MRI data, especially the plateauing relation-
ship between T2 burden of disease and disability for EDSS value
above 4.5 (Li et al., 2006), and the strong correlation between T2
lesion load change within the ﬁrst 5 years of multiple sclerosis and
disability status at 20 years of disease duration (Fisnicu et al.,
2008). It is also supported by therapeutic experience. With early
therapeutic intervention, it is now easier to demonstrate a rela-
tionship between effects on the focal inﬂammatory lesions
(relapses or new MRI lesions) and delaying conﬁrmed disability
progression in the short-term (The CAMMS223 Trial Investigators,
2008). However, at a later stage of relapsing-remitting or second-
ary progressive multiple sclerosis, the impact of these same thera-
pies on disability progression remains uncertain (Panitch et al.,
2004, Coles et al., 2006). Finally, this concept of multiple sclerosis
as a two-stage disease has obvious implications for the future
therapeutic strategies in multiple sclerosis, reinforcing the concept
of a therapeutic window of opportunity, as suggested by Coles
et al. (2006).
Acknowledgements
The authors are indebted to the patients for their participation in
the Rennes Multiple Sclerosis Database; Drs De Burghgraeve, De
Marco, Hinzelin, Lallement, Laplaud, Merienne, Taurin and
Wiertlewski for their contribution to the development of the data-
base; Prof Chaperon for his scientiﬁc expertise on data analysis;
Profs Confavreux, Debouverie, Ebers, Gonsette, Hommes,
Kremenchutzky and Narayana, for fruitful discussions and com-
ments on the manuscript; Prof Confavreux and the European
Database for Multiple Sclerosis (EDMUS) Coordinating Center
for their essential contribution to the development and update
of the EDMUS system.
Funding
Association pour la Recherche sur la Scle ´rose en Plaques (ARSEP)
and academic funding for clinical research.
References
CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW,
Lake SL, Moran S, et al. Alemtuzumab vs Interferon beta-1a in early
multiple sclerosis. N Engl J Med 2008; 359: 1786–801.
1912 | Brain 2010: 133; 1900–1913 E. Leray et al.Charcot JM. Lec ¸ons sur les maladies du syste `me nerveux faites a ` la
Salpe ´trie `re. Paris: A Delahaye; 1880.
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR,
Kooijmans MF, et al. Beneﬁt of interferon beta-1a on MSFC progres-
sion in secondary progressive MS. Neurology 2002; 59: 679–87.
Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window
of therapeutic opportunity in multiple sclerosis: evidence from mono-
clonal antibody therapy. J Neurol 2006; 253: 98–108.
Compston A. Making progress on the natural history of multiple sclero-
sis. Brain 2006; 129: 561–3.
Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1520–7.
Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying
concept. Brain 2006a; 129: 606–16.
Confavreux C, Vukusic S. Age at disability milestones in multiple sclero-
sis. Brain 2006b; 129: 595–605.
Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and pro-
gression of irreversible disability: an amnesic process. Brain 2003; 126:
770–82.
Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression
of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430–8.
Confavreux C, Compston DA, Hommes OR, McDonald WI,
Thompson AJ. EDMUS a European database for multiple sclerosis.
J Neurol Neurosurg Psychiatry 1992; 55: 671–6.
Confavreux C, Ritleng C, Debouverie M, Durand-Dubief F, Marignier R,
Androdias G, et al. Deﬁning the natural history of MS: the need for
complete data and rigorous deﬁnitions. Answer to Dr Tremlett et al.
Mult Scler 2008; 14: 1144–7.
Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W,
Baskerville J, et al. The natural history of multiple sclerosis: a geaogra-
phically based study. 5. The clinical features and natural history of
primary progressive multiple sclerosis. Brain 1999; 122: 625–39.
Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972; 34:
187–220.
Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history
of multiple sclerosis in a population-based cohort. Eur J Neurol 2008;
15: 916–21.
Ebers GC. Prognostic factors for multiple sclerosis: the importance of
natural history studies. J Neurol 2005; 252(Suppl 3): iii15–iii20.
Fisnicu LK, Brex PA, Altmann TR, Riskiel KA, Benton CE, Lanyon R, et al.
Disability and T2 MRI lesions: a 20 year follow-up of patients with
relapse onset of MS. Brain 2008; 131: 808–17.
Frischer J, Brasmow S, Lucchinetti C, Raushka H, Schimdbauer M,
Laursen H, et al. The relationship between inﬂammation and neuro-
degeneration in multiple sclerosis. Brain 2009; 132: 1175–89.
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM,
et al. Intramuscular Interferon Beta-1a for disease progression in relap-
sing multiple sclerosis. The Multiple Sclerosis Collaborative Research
Group (MSCRG). Ann Neurol 1996; 39: 285–94.
Kantarci O, Siva A, Eraksoy M, Karabudak R, Su ¨tlas N, Agaoglu J, et al.
Survival and predictors of disability in Turkish MS patients. Neurology
1998; 51: 765–72.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observa-
tions. J Am Stat Assoc 1958; 53: 457–81.
Kappos L, Freedman M, Polman C, Edan G, Hartung P, Miller DH, et al.
Effect of early versus delayed interferon beta-1b treatment on disabil-
ity after a ﬁrst clinical event suggestive of multiple sclerosis: a 3-year
follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–97.
Koch M, Mostert J, Heersema D, De Keyser J. Progression in multiple
sclerosis: further evidence of an age dependant process. J Neurol Sci
2007; 255: 35–41.
Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC.
The natural history of multiple sclerosis: a geographically bases study.
9: Observations on the progressive phase of the disease. Brain 2006;
129: 584–94.
Kurtzke JF. On the evaluation of disability in multiple sclerosis. Neurology
1961; 11: 686–94.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology 1983; 33: 1444–52.
Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bru ¨ck W, Rauschka H,
Bergmann M, et al. Cortical demyelination and diffuse white matter
injury in multiple sclerosis. Brain 2005; 128: 2705–12.
Leray E, Morrissey S, Yaouanq J, Coustans M, Le Page E, Chaperon J,
et al. Long term survival of patients with multiple sclerosis in West
France. Mult Scler 2007; 13: 865–74.
Li DK, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, et al. MRI T2
lesion burden in multiple sclerosis: a plateauing relationship with clin-
ical disability. Neurology 2006; 66: 1384–89.
Lublin FD, Reingold SC. Deﬁning the clinical course of multiple sclerosis:
results of an international survey. Neurology 1996; 46: 907–11.
Lublin FD, Baier M, Cutter G. Effect of relapse on development of resi-
dual deﬁcit in multiple sclerosis. Neurology 2003; 61: 1528–32.
Panitch H, Miller A, Paty D, Weinshenker B. North American Study
Group on interferon beta 1b in secondary progressive MS.
Neurology 2004; 63: 1788–95.
Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland
with particular references to its course and prognosis. Brain 1990; 113:
1597–628.
Poser CM, Paty DW, Scheinberg L, Mc Donald WI, Davis FA, Ebers GC,
et al. New diagnostic criteria for multiple sclerosis: guidelines for
research protocols. Ann Neurol 1983; 13: 227–31.
PRISMS Study Group (Prevention of Relapses and Disability by Interferon
beta-1a Subcutaneously in Multiple Sclerosis). Randomised double-
blind placebo controlled study of interferon beta-1a in relapsing-remit-
ting multiple sclerosis. Lancet 1998; 352: 1498–504.
Rice GP, Filippi M, Comi G. Cladribine and progressive multiple sclerosis:
clinical and MRI outcomes of a multicenter controlled trial. Cladribine
MRI Study Group. Neurology 2000; 54: 1145–55.
Runmarker B, Andersen O. Pronostic factors in a multiple sclerosis inci-
dence cohort with twenty ﬁve years of follow-up. Brain 1993; 116:
117–34.
SPECTRIMS Study Group (Secondary Progressive Efﬁcacy Clinical Trial of
Recombinant Interferon beta-1a in MS). Randomized controlled trial of
interferon-beta-1a in secondary progressive MS: Clinical results.
Neurology 2001; 56: 1496–504.
Stankoff B, Mrejen S, Tourbah A, Fontaine B, Lyon-Caen O, Lubetzki C,
et al. Age at onset determines the occurrence of the progressive phase
of multiple sclerosis. Neurology 2007; 68: 779–81.
Statistical Package for Social Science [program]. Chicago: SPSS; 2002..
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mo ¨rk S, Bo ¨ L. Axonal
transaction in the lesion of multiple sclerosis. N Engl J Med 1998; 338:
278–85.
Tremlett H, Paty D, Devonshire V. Disability progression in multiple
sclerosis is slower than previously reported. Neurology 2006; 66:
172–77.
Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of pri-
mary and secondary progressive multiple sclerosis reveals differences
and similarities. J Neurol 2009; 256: 374–81.
Tremlett H, Youseﬁ M, Devonshire V, Rieckmann P, Zhao Y. Impact of
multiple sclerosis relapses on progression diminishes with time.
Neurology 2009; 73: 1616–23.
Weiner H. The challenge of multiple sclerosis: how do we cure a chronic
heterogeneous disease? Ann Neurol 2009; 65: 239–48.
Weinshenker BG, Bass B, Rice GP, Noseworthy JH, Carriere W,
Baskerville J, et al. The natural history of multiple sclerosis: a geogra-
phically based study. I. Clinical course and disability. Brain 1989a; 112:
133–46.
Weinshenker BG, Bass B, Rice GP, Noseworthy JH, Carriere W,
Baskerville J, et al. The natural history of multiple sclerosis: a geogra-
phically based study. 2. Predictive value of the early clinical course.
Brain 1989b; 112: 1419–28.
Young PY, Lederer C, Eder K, Daumer M, Neiss A, Polman C, et al.
Relapses and subsequent worsening of disability in relapsing-remitting
multiple sclerosis. Neurology 2006; 67: 804–8.
Two-stage disability progression in MS Brain 2010: 133; 1900–1913 | 1913